Amgen Highlights Lumakras Combination Data From Solid Tumor Trials

Amgen Inc AMGN announced new combination study results from the Phase 1b CodeBreaK 101 study of Lumakras (sotorasib) for KRAS G12C-mutated cancers.
Data will be presented at the AACR-NCI-EORTC 2021 Virtual International Conference on Molecular Targets and Cancer Therapeutics.
Related: Amgen's Lumakras Combo Therapy Shows Improved Response Rate In Colorectal Cancer.
In one of the studies, Amgen combined Lumakras with Mekinist, a mitogen-activated protein kinase inhibitor (MEKi), in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and other solid tumors.
According to Amgen, just two of 18 patients with CRC achieved a partial response, one of whom had already been treated with Lumakras as a monotherapy.
In NSCLC, five of 18 patients achieved a partial response, two of whom had previously received Lumakras.
The most common side effects were diarrhea, rash, dermatitis acneiform, nausea, and vomiting, with no new safety concerns identified.
In the other study, Amgen paired Lumakras with Gilotrif, a pan-ErbB tyrosine kinase inhibitor, in 33 heavily-pretreated patients with KRAS G12C-mutated NSCLC, including five who had been treated with Lumakras as a monotherapy.
Patients were randomized to receive 20 mg of afatinib/960 mg of Lumakras or 30 mg of afatinib/960 mg of Lumakras.
The cohorts posted objective response rates of 20% and 35%, respectively.
In a separate study, Lumakras monotherapy reported a 37.1% overall response rate among 126 patients with advanced NSCLC.
Price Action: AMGN stock is up 0.04% at $210.06 during the market session on the last check Thursday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga